A Randomized, Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB-001 as Immune Modulator in Moderate COVID-19 Patients
Journal Title: Medical Journal of Clinical Trials & Case Studies - Year 2021, Vol 5, Issue 4
Abstract
Introduction: Several therapeutic agents are being evaluated for the treatment of coronavirus disease 2019 (COVID-19). PNB-001 is a potent anti-inflammatory agent with immune stimulation properties. It is a first in class CCK A agonists and CCKB antagonist, being responsible for its unique action. Methods: We conducted a multi-centre, randomized, parallel group, comparative, open label study to assess efficacy and safety of PNB-001 in patients with moderate COVID-19 infection. Patients were randomly assigned to receive PNB-001 100 mg orally with Best Care BC (PNB 001 + BC) or only Best Care (BC). A total of 40 patients (20 in Adjunct and 20 in BC arm) were randomised and received treatment. Results: The primary endpoint, change in the 8-point WHO Ordinal Scale score for COVID-19 showed significant Clinical Improvement from baseline to day 15 with PNB 001 + BC (P=0.042). Death rate, one patient on PNB 001+BC and two patients in BC arm died (1 Vs 2; HR: 2.0 [95%CI=0.18, 22.05]; P=0.56) by Day 28. Mean Chest X-ray score showed significant improvement (2.05 Vs 1.16; P=0.032) as well as more patients quickly showed complete improvement. Patients needed shorter duration of hospitalization and on day 15, 1 patient was hospitalised on adjunct compared to 5 on BC (P=0.048), thus giving 80% of reduction on the hospitalisation parameter. Mean duration of supplemental oxygen requirement was shorter. 50% of patients were off oxygen on day 6 on adjunct compared to day 8 on BC. Exploratory analysis done for ESR, CRP, IL-6, and N/L ratio and immune parameters showed a statistically significant reduction by Day 15. Lymphocytes were increased into the reference range (P=0.032) and neutrophils were reduced (P=0.013). The role of PNB-001 as immune modulator was clearly established. NLR was reduced significantly for adjunct compared to BC. A total of 24 (11 Vs 13) adverse events were reported in 18 (8 Vs 10) patients and none of the 11, were related to PNB-001. Overall safety profile was found better in test than control arm. Conclusion: PNB-001 when combined with BC improved the clinical status of patients with moderate COVID-19 infection compared to BC alone. Hospitalisation and dead rate was further reduced by 80% and 50%, respectively. PNB-001 was well tolerated by patients with moderate COVID-19 and acted by stimulation of the immune system. Key Findings: Anti-inflammatory activity was improved further for test agent PNB-001 even in presence of potent steroids. The immune stimulating properties of PNB-001, analysed in form of NLR, are key to fight COVID-19 infection. NLR was found highly useful as predictive and clinical biomarker and it was significantly reduced by PNB-001.
Authors and Affiliations
Lattmann P , Balaram PN , Nargundkar N , Bhalerao P and Lattmann E*
Keywords
Related Articles
- EP ID EP756422
- DOI 10.23880/mjccs-16000297
- Views 32
- Downloads 0
A Randomized, Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB-001 as Immune Modulator in Moderate COVID-19 Patients
Introduction: Several therapeutic agents are being evaluated for the treatment of coronavirus disease 2019 (COVID-19). PNB-001 is a potent anti-inflammatory agent with immune stimulation properties. It is a first in clas...
Expression of Cell Adhesion Molecules in Preeclampsia
Aim: The serum P-Selectin and E-Selectin levels of preeclamptic patients attending General Hospital Owerri, Nigeria were evaluated. Materials and Methods: A case control study involving 200 primigravida (100 preeclampt...
Role of Continuous Irrigation Suction (CIS) System in Wound Bed Preparation
Non healing wound is a common problem encountered by plastic surgeon. There are various causes due to which the wound becomes none healing. There are various causes for delay in wound healing like persistence of infectio...
Inherited Epidermolysis Bullosa: A Clinical Case
Epidermolysis bullosa (EB) is a rare group of disorders, clinically and genetically heterogeneus, characterized by an extreme mucosal fragility that predisposes patients to the development of blisters induced spontaneou...
The Curious Case of Pyrexia of Unknown Origin
Pyrexia of unknown origin (PUO) is a diagnostic challenge for many clinicians. The causes of PUO are diverse. Infections and malignancies are the most common causes of PUO. There are many rare causes of PUO like aorto-a...